<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-0255</journal-id>
<journal-title><![CDATA[Revista Archivo Médico de Camagüey]]></journal-title>
<abbrev-journal-title><![CDATA[AMC]]></abbrev-journal-title>
<issn>1025-0255</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Camagüey]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-02552020000400002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultados de la cicatrización con bevacizumab en la degeneración macular relacionada con la edad húmeda]]></article-title>
<article-title xml:lang="en"><![CDATA[Results of the cicatrization with bevacizumab in the age-related humid macular degeneration]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez-Pardo]]></surname>
<given-names><![CDATA[Iris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuéllar-Torres]]></surname>
<given-names><![CDATA[Olga Lidia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Ríos]]></surname>
<given-names><![CDATA[Arllety]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Pargas]]></surname>
<given-names><![CDATA[Aymed]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cardoso-Guillén]]></surname>
<given-names><![CDATA[Elías]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Camagüey Hospital Universitario Manuel Ascunce Domenech Servicio de Retina]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Camagüey Hospital Universitario Manuel Ascunce Domenech Servicio de Catarata]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-02552020000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-02552020000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-02552020000400002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento: la degeneración macular relacionada con la edad está entre las causas más comunes de pérdida visual severa e irreversible en pacientes mayores de 60 años en el mundo industrializado. Es considerado el aumento de la esperanza de vida en la población de los adultos mayores, la necesidad de un diagnóstico temprano y oportuno, es obvio para esta enfermedad que constituye un problema de salud a resolver.  Objetivo:  describir los resultados de la cicatrización con el uso del bevacizumab en la degeneración macular relacionada con la edad húmeda.  Métodos:  se realizó un estudio descriptivo, longitudinal en pacientes con el diagnóstico de degeneración macular relacionada con la edad húmeda. La población la conformaron 25 pacientes que acudieron a la consulta de retina en el periodo de octubre 2018 a abril 2019 y que cumplieron con los criterios de selección. Se les aplicó una encuesta y se estudiaron variables como: edad, sexo, antecedentes patológicos personales, número de inyecciones intravitreas colocadas a cada paciente, complicaciones post inyección y cicatrización de la lesión macular. BMMEM  Resultados:  según el comportamiento de los grupos de edades y el sexo, se encontró que la edad entre 60 y 69 fue de diez pacientes y el sexo femenino 15 pacientes fueron los más frecuentes. La hipertensión ocular fue la complicación que predominó. El antecedente patológico personal más frecuente fue la hipertensión arterial con cuatro pacientes. La mayor cantidad de ojos cicatrizaron con la administración de una y dos dosis del medicamento.  Conclusiones:  predominó el grupo de edad de 60 a 69 años y el sexo femenino. La hipertensión ocular fue la complicación más frecuente. Se constató la hipertensión arterial como el antecedente patológico personal más habitual. La cicatrización de los ojos ocurrió con la administración entre una y dos dosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  the age-related macular degeneration is among the most common causes of harsh and irreversible visual loss in patient elders of 60 years in the industrialized world. Considering the increase of life expectancy and the rise in population of the senior citizens, the need of an early and opportune diagnosis, it is obvious for this disease that constitutes a health problem we have to solve.  Objective:  to describe the results of the cicatrization with the use of the bevacizumab in the age-related humid macular degeneration.  Methods:  a descriptive, longitudinal study in patients with the diagnosis of age-related humid macular degeneration was carried out. 25 patients that attended the retinal consultation in the period October, 2018 to April, 2019 and who fulfilled the criteria constituted the population of selection. They were applied an opinion poll and they studied variables were: Age, sex, pathological personal background, number of intravitreous injections placed to each patient, complications after injection and cicatrization of the macular injury. B  Results:  according to the age groups and the sex, it was shown that the age between 60 and 69, ten patients and the feminine sex 15 patients were the most frequent. The ocular hypertension was the complication that predominated with four patients. The greatest amount of eyes healed with the administration of one and two doses of the medication.  Conclusions:  the age group from 60 to 69 years and the feminine sex predominated. The ocular hypertension was the most frequent complication. It was verified high blood pressure as the most frequent pathological antecedent. The cicatrization of the eyes happened with the administration between one and two doses.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[DEGENERACIÓN MACULAR/diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[BEVACIZUMAB/uso terapéutico]]></kwd>
<kwd lng="es"><![CDATA[CICATRIZACIÓN DE HERIDAS/efectos de los fármacos]]></kwd>
<kwd lng="es"><![CDATA[INYECCIONES INTRAVÍTREAS]]></kwd>
<kwd lng="es"><![CDATA[HIPERTENSIÓN OCULAR/complicaciones]]></kwd>
<kwd lng="en"><![CDATA[MACULAR DEGENERATION/diagnosis]]></kwd>
<kwd lng="en"><![CDATA[BEVACIZUMAB/therapeutic use]]></kwd>
<kwd lng="en"><![CDATA[WOUND HEALING/drug effects]]></kwd>
<kwd lng="en"><![CDATA[INTRAVITREAL INJECTIONS]]></kwd>
<kwd lng="en"><![CDATA[OCULAR HYPERTENSION/complications]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Degeneración macular relacionada con la edad]]></source>
<year>2012</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Jaypee-Highlights]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Tomay]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Meuer]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ten year incidence and progression of age- related maculopathy The Beaver Dam Eye Study]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2002</year>
<volume>109</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1767-79</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leibowitz]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Krueger]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Maunder]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Framingham Eye Study monograph An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration]]></article-title>
<source><![CDATA[Surv Ophthalmol]]></source>
<year>1980</year>
<volume>24</volume>
<numero>^sSuppl</numero>
<issue>^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>335-610</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Degeneración macular relacionada con la edad]]></article-title>
<source><![CDATA[Arch Argent oftalmol]]></source>
<year>2008</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>48-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naranjo Hernández]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa Linares]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cañizares Marín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Envejecimiento poblacional en Cuba]]></article-title>
<source><![CDATA[Gac Méd Espirit]]></source>
<year>2015</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>National Eye Institute</collab>
<source><![CDATA[Vision problems in the US: prevalence of adult visión impartiment and age-related disease in Americans]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Maryland ]]></publisher-loc>
<publisher-name><![CDATA[Bethesida]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baguer Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Casado Triana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco García]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Cid Vásquez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínico epidemiológicas de la degeneración macular relacionada con la edad en un área de salud]]></article-title>
<source><![CDATA[GeroInfo]]></source>
<year>2012</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yates]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic susceptibility to age related macular degeneration]]></article-title>
<source><![CDATA[J Med Genet]]></source>
<year>2000</year>
<volume>37</volume>
<page-range>83-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Aragón]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Degeneración Macular Asociada a la Edad (DMAE) y calidad de visión]]></source>
<year>2017</year>
<page-range>1-10</page-range><publisher-name><![CDATA[Gaceta Artículo Científico]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Singh K]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[ElShelmani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mansergh]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Wride]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Padilla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk Factors and Biomarkers of Age-Related Macular Degeneration]]></article-title>
<source><![CDATA[Prog Retin Eye Res]]></source>
<year>2016</year>
<volume>54</volume>
<page-range>64-102</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schatat]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Leske]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension, cardiovascular disease, and age-related macular degeneration]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>2000</year>
<volume>118</volume>
<page-range>351-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez Fernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Domínguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Ferreiro]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en degeneración macular asociada a la edad]]></article-title>
<source><![CDATA[Tthea Info]]></source>
<year>2014</year>
<numero>69</numero>
<issue>69</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gass]]></surname>
<given-names><![CDATA[JDM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drusen and disciform macular detachment and degeneration]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1973</year>
<volume>90</volume>
<page-range>206-17</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[de Amorim Garcia Filho]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Yehoshua]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Martidis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tennant]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age-related macular degeneration]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Yanoff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duker]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[Ophthalmology]]></source>
<year>2014</year>
<edition>4th</edition>
<page-range>6-28</page-range><publisher-loc><![CDATA[Philadelphia, PA ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanski]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bowling]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Oftalmología clínica]]></source>
<year>2012</year>
<edition>7</edition>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yonekawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and current treatment on age-related macular degeneration]]></article-title>
<source><![CDATA[Cold Spring Harb Perspect Med]]></source>
<year>2015</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>a017-178</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>American Academy of Ophthalmology</collab>
<source><![CDATA[Preferred Practice Pattern: Age-related macular degeneration]]></source>
<year>2015</year>
<publisher-loc><![CDATA[San Francisco, CA ]]></publisher-loc>
<publisher-name><![CDATA[American Academy]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>American Academy of Ophthalmology</collab>
<source><![CDATA[Age-related macular degeneration]]></source>
<year>2019</year>
<publisher-loc><![CDATA[San Francisco, CA ]]></publisher-loc>
<publisher-name><![CDATA[American Academy]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monje Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dolz Marco]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Andreu Fenoll]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fornés Ferrer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gallego Pinazo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidencia y resultados clínicos de las distintas formas neovasculares de degeneración macular asociada a la edad en Valencia (España)]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol]]></source>
<year>2018</year>
<volume>93</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>324-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wormald]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Smeeth]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Henshaw]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Photodynamic therapy for neovascular age-related macular degeneration]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2005</year>
<numero>4</numero>
<issue>4</issue>
<page-range>CD002030</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hooper]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Guymer]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New treatments in age-related macular degeneration]]></article-title>
<source><![CDATA[Clin Exp Ophthalmol]]></source>
<year>2003</year>
<volume>31</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>376-91</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Castellanos]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Espósito]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Crim]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barros-Centeno]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bevacizumab intravítreo en el tratamiento de las oclusiones venosas de la retina]]></article-title>
<source><![CDATA[Rev Methodo]]></source>
<year>2017</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>59-64</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dana Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González-Castellanos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barros Centeno]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Guantay]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Serra]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bevacizumab intravítreo como tratamiento de maculopatías miópicas neovasculares]]></article-title>
<source><![CDATA[Rev Methodo]]></source>
<year>2017</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>55-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Vicente]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Morales]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Galván Carrasco]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Castilla Lázpita]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vital Berral]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaro Juárez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bevacizumab intravítreo en el tratamiento de la maculopatía por radiación]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol]]></source>
<year>2017</year>
<volume>92</volume>
<page-range>283-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maguire]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age-related macular degeneration]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Gault]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vander]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[Ophthalmology Secrets in Color]]></source>
<year>2015</year>
<edition>4th</edition>
<page-range>300-10</page-range><publisher-loc><![CDATA[Philadelphia, PA ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrison Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Carrillo]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Degeneración macular relacionada con la edad]]></article-title>
<source><![CDATA[Acta méd Grupo Ángeles]]></source>
<year>2017</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rio Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Argones]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Silva]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Oftalmología, diagnóstico y tratamiento. Sección VI Retina]]></source>
<year>2018</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Sandvik]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bragadottir]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2015</year>
<volume>122</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>146-52</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmucker]]></surname>
<given-names><![CDATA[Cl]]></given-names>
</name>
<name>
<surname><![CDATA[Loke]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Ehlken]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Agostini]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Antes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age related macular degeneration a safety review]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2011</year>
<volume>95</volume>
<page-range>308-17</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caballero Abdala]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca Rodriguez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nieto Moreno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tuesca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de los cambios en la presión intraocular luego de inyección intravítrea de antiangiogénicos]]></article-title>
<source><![CDATA[Rev Soc Colomb Oftalmol]]></source>
<year>2014</year>
<volume>47</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>294-302</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
